I am an assistant attending physicist with expertise in applying high-performance radiation transport algorithms to the analysis of occupational radiation safety and epidemiology. The overarching goal of my research is to deepen our understanding of exposure to ionizing radiation and its subsequent adverse health effects. My research has primarily focused on the unintentional intake of radionuclides along with external exposure to radionuclides and radiation-generating devices. Additionally, my research involves quantifying the risk associated with non-acute radiation exposures by supporting the epidemiology of large cohorts of occupationally exposed radiation workers through historical internal and external dose reconstruction.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael Bellamy discloses the following relationships and financial interests:
-
National Academies of Sciences, Engineering, and Medicine
Professional Services and Activities (Uncompensated) -
National Council on Radiation Protection and Measurements
Professional Services and Activities (Uncompensated)
-
National Institutes of Health (NIH)
Professional Services and Activities (Uncompensated)
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures